Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Gynecologic 1

Conditions

Ovarian Neoplasms 57Carcinoma, Ovarian Epithelial 28Fallopian Tube Neoplasms 20Uterine Cervical Neoplasms 17Endometrial Neoplasms 17Breast Neoplasms 13Stomach Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Lung Neoplasms 9Prostatic Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Parkinson Disease 4, Autosomal Dominant Lewy Body 7Esophageal Neoplasms 7Carcinoma, Renal Cell 7Peritoneal Neoplasms 6Melanoma 6Uterine Neoplasms 4Urinary Bladder Neoplasms 4Small Cell Lung Carcinoma 4Sarcoma 4Pancreatic Neoplasms 4Neoplasms 4Head and Neck Neoplasms 4Esthesioneuroblastoma, Olfactory 4Colorectal Neoplasms 4Carcinoma, Transitional Cell 4Triple Negative Breast Neoplasms 3Salivary Gland Neoplasms 3Kidney Neoplasms 3Brenner Tumor 3

Interventions

Carboplatin 17Filgrastim 16Ifosfamide 13Etoposide 13Paclitaxel 11Peripheral Blood Stem Cell Transplantation 10Cisplatin 6Thiotepa 5Therapeutics 5Cyclophosphamide 5Temozolomide 4Psychiatric Rehabilitation 4Polymerase Chain Reaction 4Granulocyte Colony-Stimulating Factor 4Flow Cytometry 4Bleomycin 4Taxes 3Radiotherapy 3Methylprednisolone 3Magnetic Resonance Spectroscopy 3Amplified Fragment Length Polymorphism Analysis 3Amifostine 3sargramostim 2pegfilgrastim 2liposomal amphotericin B 2ixabepilone 2etoposide phosphate 2aldesleukin 2aflibercept 2Trastuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Testicular Neoplasms × Docetaxel × Gynecologic × Clear all
NCT00002903 2012-07-02

Docetaxel in Treating Patients With Recurrent or Refractory Germ Cell Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
25 enrolled
GenitourinaryGynecologic

Testicular Germ Cell Tumor, Ovarian Neoplasms, Testicular Neoplasms, Seminoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡